Joshua Brumm

Josh is a General Partner at Forbion. He has extensive experience in building and leading companies in biotech and healthcare. Previously, Josh was the president and CEO of Dyne Therapeutics. He led Dyne through its initial public offering on Nasdaq in 2020, and advanced two rare muscle disease programs into clinical trials. Prior to Dyne, he held leadership roles at several other biotechs, including Proteolix, Pharmacyclics and ZELTIQ Aesthetics, all of which were acquired by large pharmaceutical companies.

Earlier, he served as chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its IPO and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Josh was COO and CFO at Versartis, where he spearheaded the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its IPO, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking positions at Citigroup Global Markets, Inc. and Morgan Stanley.

Over the course of his career, Josh has raised ~$2.5 billion in capital. Josh holds a B.A. in business administration from the University of Notre Dame.